QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 发表日期：2016    专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 A randomized trial comparing multiband mucosectomy and cap-assisted endoscopic resection for endoscopic piecemeal resection of early squamous neoplasia of the esophagus 期刊论文 2016, 卷号: 48, 期号: 4, 页码: 330-338 作者:  Zhang, Yue-Ming;  Boerwinkel, David F.;  Qin, Xiumin;  He, Shun;  Xue, Liyan 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文 2016, 卷号: 17, 期号: 5, 页码: 577-589 作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04 Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Lu, Shun;  Mok, Tony;  Lu, You;  Zhou, Jianying;  Shi, Yuankai 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04 Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Lu, Shun;  Mok, Tony;  Lu, You;  Zhou, Jianying;  Shi, Yuankai 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cance 期刊论文 2016, 卷号: 12, 期号: 4, 页码: 380-387 作者:  Wang, Luhua;  Wu, Yi-Long;  Lu, Shun;  Deng, Lei;  Ahn, Myung-Ju 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 Asians  carcinoma  chemoradiotherapy  combined modality therapy  non-small cell lung